The Potential of Metabolic Interventions to Enhance Transdermal Drug Delivery  by Elias, Peter M. et al.
The Potential of Metabolic Interventions to Enhance Transdermal
Drug Delivery
Peter M. Elias, Janice Tsai,w Gopinathan K. Menon,n Walter M. Holleran, and Kenneth R. Feingold
Dermatology and Medical (Metabolism) Services,Veterans A¡airs Medical Center, Department of Dermatology and Medicine, University of California
San Francisco, California, U.S.A.; nGlobal Research & Development Department, Avon Products, Inc. Su¡ern, NewYork, NewYork, U.S.A.; wDepartment
of Clinical Pharmacy, National Cheng Kung University,Taiwan
The stratum corneum is a complex tissue that is meta-
bolically active, and undergoes dynamic structural
modi¢cations due to the presence of several self-regulat-
ing enzymatic systems. A large number of defensive
(protective) functions are embodied in this tissue, each
with its own structural and biochemical basis. More-
over, the stratum corneum is responsive to external per-
turbations to the permeability barrier, upregulating
a variety of metabolic processes aimed at restoring
normal barrier function. Traditional drug delivery
methods, which are of limited e¡ectiveness, view the
stratum corneum as a static, but semipermeable mem-
brane. In contrast, newer metabolically based methods,
which can be deployed alone, or in conjunction with
standard methods, have been shown to expand the spec-
trum of drugs that can be delivered transdermally in
hairless mouse epidermis. Yet, while these new ap-
proaches hold great promise, if equally e¡ective in hu-
man skin, they pose new questions about the risks of a
highly permeabilized stratum corneum. Key words:Stra-
tum corneum/barrier function/transdermal/lipid metabolism
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UNIQUE ORGANIZATION AND PROPERTIES OF
STRATUM CORNEUM (SC)
T
he paper-thin SC is a composite material made of
proteins and lipids that are crucial for life in a terres-
trial environment. In the traditional view, the SC is
regarded as impermeable, but inert and highly resili-
ent, analogous to a sheet of plastic wrap. According
to this model, transdermal permeation is governed solely by the
physical-chemical properties of this supposedly homogenous tis-
sue (Scheuplein and Blank, 1971), and barrier properties can be
assessed readily in vitro, in either devitalized or fresh epidermal
sheets. Site-related variations in the number of SC cell layers,
which govern the di¡usion path length, again can be integrated
into kinetics predicted by the plastic-wrap model.
The ¢rst development to cast doubt upon both the plastic-
wrap model and its suppositions, was the discovery of the unique
structural heterogeneity of the SC; i.e., its ‘‘bricks and mortar’’
organization (Elias, 1983). Rather than being uniformly dis-
persed, the lipids in normal SC are sequestered within the extra-
cellular spaces, where they are organized into lamellar bilayers
that surround the corneocytes (Elias, 1983; Elias and Menon,
1991). Hence, instead of thickness of the SC ‘‘membrane’’, varia-
tions in lamellar membrane structure and in total lipid content
provide the structural and biochemical basis for site-related var-
iations in permeability (Lampe et al, 1983). It follows, then, that
the extracellular, lipid-enriched matrix of the SC comprises not
only the structure that limits transdermal delivery of hydrophilic
drugs, but also the so-called SC ‘‘reservoir’’ (Nemanic and Elias,
1980).
Human SC typically comprises about 20 corneocyte cell layers,
which di¡er in their thickness, packing of keratin ¢laments, ¢lag-
grin content, and number of corneodesmosomes, depending on
body site. Corneocytes are surrounded by a highly cross-linked,
resilient sheath, the corni¢ed envelope (CE), whereas the cell in-
terior is packed with keratin ¢laments surrounded by a matrix
composed mainly of ¢laggrin and its breakdown products. Indi-
vidual corneocytes, in turn, are surrounded by a lipid-enriched
extracellular matrix, organized largely into lamellar bilayers,
which derive from secreted lamellar body (LB) precursor lipids.
Following secretion, LB contents fuse end-to-end, forming pro-
gressively elongated membrane bilayers (Elias and Menon, 1991),
a sequence mediated by a battery of lipolytic ‘‘processing’’ en-
zymes (see below). Yet, despite the clear importance of corneo-
cytes both as spacers and as a sca¡old for the extracellular
matrix, transdermal drug development has focused primarily on
manipulations of the extracellular lipid milieu (Flynn, 1989;
Schaefer and Redelmeier, 1996). The existence of aqueous pores
(Menon and Elias, 1997) not only adds further complexity to the
extracellular pathway, but also additional opportunities for novel
delivery strategies.
The exceptionally low permeability of normal SC to water-so-
luble drugs is the consequence of several characteristics of the li-
pid-enriched, extracellular matrix (Table I), including the highly
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convoluted and tortuous extracellular pathway created by cor-
neocyte ‘‘spacers’’ (Potts and Francoeur, 1991). Moreover, not only
the bilayered arrangement of extracellular lipids, but also their
extreme hydrophobicity, and their occurence in a critical (1:1:1)
molar ratio of the three key species, ceramides (Cer), cholesterol
(Chol), and free fatty acids (FFA) (Man et al, 1993), are further
characteristics that provide for barrier function.
Ceramides account for about 50% of total SC lipid mass
(Schurer and Elias, 1991;Wertz and Downing, 1991), and are cru-
cial for the lamellar organization of the SC barrier (Bouwstra et
al, 1996). Of the seven Cer classes, acylceramides or Cer 1, which
contains o-hydroxy-linked, essential fatty acids in an amide link-
age, are believed to be uniquely important for the barrier (Wertz
and Downing, 1983). Chol, the second most abundant lipid by
weight in the SC, promotes the intermixing of di¡erent lipid
species, and regulates its ‘‘phase’’ behavoir (Norlen et al, 1999).
FFA, which account for 10%^15% of SC lipids, consist predomi-
nantly of very long-chain, saturated species with 4 20 carbon
atoms (Wertz and Downing, 1991). A decrease in the concentra-
tions of any of these critical lipid species compromises barrier in-
tegrity, by altering the molar ratio required for normal barrier
function (Man et al, 1995).
The ‘‘domain-mosaic model’’ advocates a meandering, polar
(pore) pathway for water transport through grain boundaries
within the lipid mosaic (Forslind, 1994), adding potential com-
plexity to the already tortuous, extracellular pathway. The mor-
phologic basis of the aqueous pore pathway (Flynn, 1989),
however, instead appears to be lacunar domains embedded with-
in the lipid bilayers (Menon and Elias, 1997). These lacunae corre-
spond to sites of subjacent corneodesmosome degradation
(Haftek et al, 1998).Whereas these lacunae are scattered and dis-
continuous under basal conditions, following certain types of
permeabilization (e.g., occlusion, prolonged hydration, sono-
phoresis, iontophoresis), they expand until they interconnect,
forming a continuous ‘‘pore pathway’’. The pore pathway reverts
back to its original, discontinuous state once the permeabilizing
stimulus disappears. Such a lacunar system, then, does not corre-
spond to the grain boundaries of the ‘‘domain mosaic model’’, but
instead it forms an ‘‘extended macrodomain mosaic’’ within the
SC interstices (Menon et al, 1998).
EPIDERMAL LIPID SYNTHESIS, SECRETION, AND
PROCESSING
Biosynthetic activities Epidermal di¡erentiation is a vectorial
process that is accompanied by dramatic changes in lipid
composition, including loss of phospholipids with the
emergence of Cer, Chol, and FFA in the SC (Schurer and Elias,
1991; Wertz and Downing, 1991). Although epidermal lipid
synthesis is both highly active and largely autonomous from
systemic in£uences, it can be modi¢ed by external in£uences;
i.e., changes in permeability barrier status (Feingold, 1991). Acute
perturbations of the permeability barrier in mice stimulate a
characteristic recovery sequence that leads to restoration of
normal function over about 72 h in young skin (the cutaneous
stress test). This sequence includes an increase in Chol, FA, and
Cer synthesis that is restricted to the underlying epidermis, and
attributable to a prior increase in mRNA and enzyme activity/
mass for each of the key synthetic enzymes. Furthermore,
synthesis of each of the three key lipids is required for normal
barrier homeostasis; i.e., topically applied inhibitors of the key
enzymes in each pathway produce abnormalities in permeability
barrier homeostasis (cited in Feingold, 1991). These experiments
provided the seminal observations, as well as the model (‘‘stress
test’’) that led to development of a biochemical strategy to
enhance transdermal drug delivery (see below).
Lamellar body secretion The unique two-compartment
organization of the SC is attributable to the secretion of LB-
derived lipids and colocalized hydrolases at the stratum
granulosum (SG)^SC interface (Elias and Menon, 1991). Under
basal conditions, LB secretion is slow, but su⁄cient to provide
for barrier integrity. Following acute barrier disruption, calcium
is lost from the outer epidermis, and much of the preformed pool
of LB in the outermost SG cell is quickly secreted (Menon et al,
1992a, 1994). Calcium (Caþþ ) is an important regulator of LB
secretion, with the high levels of Caþþ in the SG restricting
LB secretion to low, maintenance levels (Lee et al, 1992).
Although exposure to high Caþþ (and Kþ ) delays barrier
recovery following acute perturbations, this delay is reversible
by coapplications of L-type Caþþ channel or calmodulin
inhibitors (Lee et al, 1992). Finally, barrier homeostasis and LB
secretion are regulated not only by changes in Caþþ
concentrations, but also by agents that block organellogenesis
and secretion; e.g., monensin and brefeldin A (Man et al, 1995)
(see also below). These experiments provide further potential,
biochemical approaches to enhance drug delivery.
Extracellular processing Extrusion of LB contents at the SG/
SC interface is followed by processing into mature, lamellar
membrane unit structures (Elias and Menon, 1991). As noted
above, marked alterations in lipid composition occur, including
depletion of glucosylCer and phospholipids, and cholesterol
sulfate with accumulation of Cer, FFA, and Chol in the SC. This
sequence, called extracellular processing (ECP), is attributable to
the secretion of hydrolytic enzymes that convert cosecreted LB-
derived lipid precursors into the nonpolar species that form the
membrane bilayer system (Elias and Menon, 1991). Direct
evidence for the central role of ECP in barrier homeostasis came
¢rst from studies on glucosylCer-to-Cer processing. For example,
applications of speci¢c, conduritol-type inhibitors of b-
glucocerebrosidase (b-GlcCer’ase) both delayed barrier recovery
after acute perturbations, and produced a progressive
abnormality in barrier function when applied to intact skin
(Holleran et al, 1993). Moreover, both in a transgenic murine
model of Gaucher disease (GD), produced by targeted
disruption of the b-GlcCer’ase gene (Holleran et al, 1994), and in
the severe, type 2 neuronopathic form of GD, infants present
with a barrier abnormality (Sidransky et al, 1996). The functional
de¢cit in all three models (inhibitor, transgenic murine, type 2
GD) was attributable to accumulation of glucosylCer, depletion
of Cer, and persistence of immature LB-derived membrane
structures within the SC interstices.
Phospholipid hydrolysis, catalyzed by one or more 14 kDa
secretory phospholipases (sPLA2), generates a family of
nonessential FFA, which are required for barrier homeostasis
(Mao-Qiang et al, 1995; 1996). As applications of either
bromphenacylbromide (BPB) or MJ33 (chemically unrelated
sPLA2 inhibitors) modulate barrier function in intact murine
skin, sPLA2 appears to play a critical role in barrier homeostasis
(Mao-Qiang et al, 1995; 1996). Moreover, applications of either
inhibitor to perturbed skin sites delays barrier recovery.
Sphingomyelin hydrolysis by acidic sphingomyelinase
(aSMase) generates two of the seven members of the Cer family
required for normal barrier homeostasis. Moreover, patients with
mutations in the gene encoding aSMase (Tay-Sachs,Type A) that
Table I. How stratum corneum lipids mediate barrier
function
1. Extracellular localization (only intercellular lipids play role)
2. Amount of lipid (lipid wt %)
3. Elongated, tortuous pathway (increases di¡usion path length)
4. Organization into lamellar membrane structures
5. Hydrophobic composition (absence of polar lipids and presence of
very long chain, saturated fatty acids)
6. Correct molar ratio (approximately 1:1:1 of three key lipids: ceramides,
cholesterol, and free fatty acids)
7. Unique molecular structures (e.g., acylceramides)
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lead to low enzyme activity, display an ichthyosiform dermatosis,
and transgenic mice with an absence of aSMase demonstrate a
barrier abnormality. Finally, applications of nonspeci¢c
inhibitors of aSMase to perturbed murine skin sites lead to a
delay in barrier recovery (Schmuth et al, 2000). Hence, aSMase
represents another key ECP enzyme that in theory, could be
manipulated to enhance drug delivery.
Just as with glucosylCer and sphingomyelin, Chol SO4
content increases during epidermal di¡erentiation, and then
decreases progressively as Chol SO4 is desulfated during passage
from the inner to the outer SC (Elias et al, 1984). Both Chol
sulfate and its processing enzyme, steroid sulfatase, are
concentrated in SC membrane domains, and the content of
Chol sulfate in these sites increases by approximately 10-fold
(Elias et al, 1984) in recessive X-linked ichthyosis (RXLI). Not
only is RXLI characterized by a barrier defect (Zettersten et al,
1998), but also repeated applications of Chol SO4 to intact
murine skin produce a barrier abnormality (Maloney et al, 1984).
In both cases, the barrier abnormality is attributable to Chol
SO4-induced phase separation in lamellar membrane domains
(Zettersten et al, 1998). But the barrier defect may also be, in
part, attributed to the fact that Chol SO4 is a potent inhibitor
of HMGCoA reductase (Williams et al, 1992). In summary,
manipulation of a variety of ECP enzymes represents a cohort
of potential biochemical methods that can be employed to
manipulate drug delivery.
Acidi¢cation That the SC displays an acidic external pH (‘‘acid
mantle’’) is well documented, but its origin is not known. Extra-
epidermal mechanisms, including both surface-deposited eccrine
and sebaceous gland-derived products, and metabolites of
microbial metabolism, as well as endogenous catabolic processes,
such as phospholipid-to-free FFA hydrolysis, and deimination of
histidine to urocanic acid have been proposed to in£uence SC
acidity. Protons can also be generated locally in the lower SC by
sodium-proton antiporters inserted into the plasma membrane
(Behne et al, in press). Moreover, if the limiting membrane of
the LB contains energy-dependent proton pumps (Chapman
and Walsh, 1989), then active acidi¢cation of the extracellular
space (ECS) could also accompany insertion of such pumps
coincident with LB secretion. Thus, ongoing proton secretion at
the SG/SC interface, coupled with one or more of the other
mechanisms described above, could explain not only the pH
gradient across the SC interstices, but also selective acidi¢cation
of membrane microdomains.
The concept that acidi¢cation is required for permeability
barrier homeostasis is supported by the observation that barrier
recovery is delayed when acutely perturbed skin sites are
immersed in neutral pH bu¡ers (Mauro et al, 1998), or when
either the sodium-proton antiporter (NHE1) or sPLA2-
mediated, phospholipid catabolism to FFA (Fluhr et al, 2001;
Behne et al, in press) is blocked. Acidi¢cation appears to impact
barrier homeostasis through regulation of ECP enzymes, such as
b-GlcCer’ase and aSMase, which exhibit acidic pH optima.
Whether altering pH alone could facilitate transdermal drug
delivery, and serve as an independent or additive-enhancing
method remains unknown (see below).
OVERVIEWOF STRATEGIES TO ENHANCE
TRANSDERMAL DRUG DELIVERY
Because of its theoretical advantages, enormous e¡orts have been
expended on the development of new approaches to enhance
transdermal drug delivery. Yet, despite these e¡orts, the current
list of drugs that have been delivered transdermally for systemic
applications is small (o 10), and limited to highly lipophilic com-
pounds of both low molecular weight, and low total absorbed-
dose (e.g., nitroglycerin, clonidine, sex steroids, scopolamine,
and nicotinic acid).We will now provide a brief overview of cur-
rent transdermal technology, before proceeding to a discussion of
biochemical/metabolic approaches.
The strategies that have been devised to enhance transdermal
drug delivery can be classi¢ed as either physical, chemical, me-
chanical, or biochemical approaches. Combinations of these stra-
tegies can also be employed to increase e⁄cacy (Johnson et al,
1996; Tsai et al, 1996; Choi et al, 1999), or for extending the time
available for transdermal delivery (see below). Physical techniques
vary from straightforward approaches, such as occlusion and tape
stripping, to highly sophisticated instrumentation and miniaturi-
zation (e.g., iontophoresis, electroporation). The most straightfor-
ward of physical methods is prolonged occlusion, which alters
the barrier properties of SC (Van Den Merwe and Ackermann,
1987; Mikulowska, 1992). Following 24^48 h of occlusion with
resultant hydration, corneocytes swell, the intercellular spaces
become distended, and the lacunar network becomes dilated.
Distention of lacunae eventually leads to connections within an
otherwise discontinuous system, creating ‘‘pores’’ in the SC inter-
stices through which polar and nonpolar substances can penetrate
more readily.
Another straightforward physical method to abrogate the bar-
rier is removal of portions of the SC by stripping with either ad-
hesive tapes or cyanoacrylate glue. Sequential stripping increases
transepidermal water loss (TEWL), an indicator of a barrier de-
fect, which correlates well with enhanced transdermal drug deliv-
ery (Spruit and Malten, 1966). Tape stripping removes both
corneocytes and extracellular lipids, thereby reducing the tortu-
ous path length that these substances would otherwise need to
traverse. Moreover, stripping mechanically disrupts lamellar bi-
layers, even in retained, lower SC layers.Whereas barrier disrup-
tion with stripping is accomplished readily in animal skin,
however, human skin requires many more strippings to obtain
comparable results, which can result in mast cell degranulation
and in£ammation, leading to discomfort and pain. Moreover,
tape stripping in humans, with or without attendant irritation,
is complicated by the tendency for more pigmented skin to de-
velop postin£ammatory hyperpigmentation, and more strippings
are required to disrupt the barrier inType 5 and 6 pigmented skin
(Reed et al, 1995).
Iontophoresis and electroportation represent electrically as-
sisted, physical approaches to enhance delivery of drugs/macro-
molecules across the SC (Banga et al, 1999). Iontophoresis uses
low currents from an externally placed electrode, with the same
charge as the net polarity of the drug, to drive these molecules
across the SC.Whereas the predominant pathway of iontophore-
tic transport reportedly is transappendageal (hair follicles, sweat
glands), extracellular routes across the SC are also traversed
(Monteiro-Riviere et al, 1994). Iontophoretic delivery through
the SC interstices occurs via aqueous pores; and thus it operates
at both a macro- (appendegeal) and a micro- (extracellular, lacu-
nar) level. As drug delivery is proportionate to the amount
of applied current, iontophoresis o¡ers an opportunity for pro-
grammable drug delivery (Green, 1996), especially with the recent
development of both miniaturized microprocessor systems and
disposable hydrogel pads. Electroporation (electropermeabiliza-
tion) is a relatively new electrical, nonthermal method, which
employs ultrashort pulses with large transmembrane voltages
100V to induce structural rearrangement and conductance
changes in membranes, again leading to pore formation (Banga
et al, 1999). Most e¡ective for single bilayer cell membranes, elec-
troporation also permeabilizes human SC (Prausnitz et al, 1993;
Weaver and Chizmadzev, 1996). Although pore formation again
is considered to be the subcellular mechanism, the actual pathway
across SC has not yet been visualized.
Ultrasound, which is employed extensively in both medical
diagnostics and physical therapy, is considered safe, with no
known short- or long-term side-e¡ects. Upon encountering the
SC, ultrasound waves generate defects in SC structure (Wu et al,
1998), leading to permeabilization of the SC. Although frequency
ranges of 1^3MHz are minimally e¡ective, higher frequencies
(10^20MHz) signi¢cantly enhance drug delivery (Bommannan
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et al, 1992a). During sonophoresis, electron-dense tracers, such as
lanthanum and FITC-conjugated dextrans, penetrate across the
SC into the epidermis and dermis within 5min with no apparent
damage to the keratinocytes (Bommannan et al, 1992b; Menon
et al, 1994). Moreover, tracer movement again occurs through la-
cunae, which become dilated and transiently continuous, fol-
lowed by collapse of the pore pathway with cessation of applied
energy (Menon et al, 1997b).
A recently developed technique utilizes pulsed laser beams to
generate photomechanical (stress) waves that interact directly
with the SC in ways that are di¡erent from ultrasound (Lee et al,
1992; 1999). These waves are generated by ablation of a target ma-
terial (polystyrene) that covers the drug-containing solution that
is to be delivered. The target ¢rst absorbs the laser radiation, and
the solution then serves as a coupling medium for stress waves to
propagate across the SC. As with sonophoresis and iontophoresis,
the pathway of permeation is thought to be extracellular, but
morphologic studies are lacking. In murine models, 40 kDa dex-
tran molecules and 20 nm latex particles were delivered across the
SC by a single photomechanical wave, generated using a 23-ns
Q-switched Ruby laser. As with sonophoresis and iontophoresis,
single photomechanical compression waves modulate the perme-
ability of human SC only transiently, and barrier function re-
covers almost immediately. Recently, this method has been used
to deliver small molecules (e.g., 5-aminolevulenic acid) into hu-
man skin without discomfort, and without adverse e¡ects on
skin structure or viability (Lee et al, 1999).
A variety of solvents (ethanol, methanol, chloroform, acetone)
and detergents can extract SC barrier lipids and permeabilize the
SC. Morphologic changes in human SC following exposure to
solvents (Menon et al, 1998) show extraction, phase separation, de-
rangement of lamellar bilayers, and often the creation of defects
in corneocytes. Moreover, surfactants, such as sodium lauryl sul-
fate (SDS), and vehicles (e.g., propylene glycol) extract lipids and
create extensive expansion of pre-existing lacunar domains. Sol-
vent-based penetration enhancers, such as azone, sulfoxides, urea,
and FFA, not only extract extracellular lipids, but they also alter
SC lipid organization (phase behavior), thereby increasing trans-
dermal delivery (Santus and Baker, 1993). Finally, liposomes re-
present yet another ‘‘chemical’’ method, frequently employed to
enhance drug delivery; however, liposomes appear to enhance
transdermal delivery solely via the appendegeal pathway (Yarosh
et al, 1994; Domashenko and Cotsarelis, 1999), as yet there is no
convincing evidence that they penetrate intact SC (Lasch et al,
1991; Korting et al, 1995).
METABOLIC APPROACHES TO ENHANCE
TRANSDERMAL DRUG DELIVERY
As noted above, a wide variety of methods have been deployed to
enhance transdermal drug delivery. Yet, despite their apparent ef-
¢cacy in vitro, or in animal models, they have not yet been shown
to be e¡ective without attendant toxicity in humans. A major
problem with most of these approaches is their standard assess-
ment in vitro, using devitalized human skin. Non-viable samples
do not mount a metabolic response against barrier perturbations,
and such in vivo responses inevitably restrict the e⁄cacy of any
enhancing method, i.e., they ‘‘slam the window shut’’. An alter-
nate or concurrent approach aims to enhance the e⁄cacy of stan-
dard enhancers by interfering with the repair (metabolic)
response in murine skin in vivo (Tsai et al, 1996) (Fig 1). Some of
these methods can also abrogate the barrier in intact skin by
‘‘opening the window’’, thereby obviating the requirement for
pretreatment or cotreatment with a primary enhancer.
The concept of a biochemical approach to enhance transdermal
drug delivery came from pharmacologic studies in mice, where
key metabolic sequences that restore and maintain barrier func-
tion were inhibited, i.e., epidermal lipid synthesis, LB secretion,
ECP, and maintenance of lamellar bilayers (Table 2). All of these
methods have the net e¡ect of either altering the critical molar
ratio of the three key SC lipids, or inducing discontinuities in
the lamellar bilayer system.The ¢rst pharmacologic study in sup-
port of this concept came from experiments in adult hairless mice
where topical HMGCoA reductase inhibitors, such as lovastatin
and £uvastatin, caused both a delay in barrier recovery (Feingold
et al, 1990) and a barrier defect following repeated applications to
intact skin (Feingold, 1992). As the ability of the inhibitors to al-
ter barrier homeostasis could be reversed by coapplications of
either mevalonate (the immediate product of HMGCoA reduc-
tase) or Chol (a distal product), the inhibitor e¡ect could not be
ascribed to nonspeci¢c toxicity. Likewise, application of speci¢c
pharmacologic inhibitors of ACC (Mao-Qiang et al, 1993), serine
palmitoyl transferase (SPT) (Holleran et al, 1991), and glucosylCer
synthase (Chujor et al, 1998), key enzymes of FA and Cer synth-
esis, respectively, also provoked a delay in barrier recovery, as
measured by TEWL. Yet, whereas the HMGCoA reductase and
ACC inhibitors are additive in their capacity to alter barrier
recovery, coapplications of HMGCoA reductase and SPT in-
hibitors instead paradoxically normalize the kinetics of
barrier recovery (Mao-Qiang et al, 1993). Whereas these studies
Figure1. Barrier recovery following acute perturbations. Applica-
tion of metabolic enhancer causes a delay in barrier recovery, creating a
potential ‘‘window’’ for enhanced transdermal drug delivery.
Table II. Mechanistic classi¢cation of various biochemical
enhancers
Lipid Synthesis Inhibitors
HMGCoA reductase
Acetyl CoA carboxylase
Serine palmitoyl transferase
Glucosylceramide synthase
Lamellar Body Secretion Inhibitors
Organellogenesis
Golgi processing
Exocytosis
Extracellular Acidi¢cation Inhibitors
Protonophores
Proton pumps
Extracellular Processing
b-Glucocerebrosidase
Secretory phospholipase A2
Acidic sphingomyelinase
Steroid sulfatase
Ion pump/channel inhibitors
Membrane Bilayer Assembly
Lipids analogues
Complex lipids
Lipid hydrolases
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determined metabolic events required for permeability barrier
homeostasis, we noted that these inhibitors also caused the ‘‘win-
dow to remain open longer’’, and/or they could ‘‘open the
window’’ for transdermal drug delivery. Thus, all of the pharma-
cologic ‘‘knockout’’ studies support the concept that interference
with the biosynthesis of any of the key SC lipids can lead to a
temporary increase in TEWL, with obvious implications for
transdermal drug delivery.
In addition to lipid synthesis inhibitors, agents that interfere
with LB assembly, secretion, or ECP delay barrier recovery after
acute perturbations, and in some cases, create defects in intact
skin (Table III). Examples include: (a) brefeldin A, which blocks
LB assembly by disorganizing preformed Golgi structures; (b)
monensin or chloroquin, which inhibit the apical translocation
and secretion of LB; (c) high Caþ þ /Kþ levels, which inhibit
LB secretion; (d) inhibitors of b-GlcCer’ase, aSMase, and sPLA,
which are required for normal ECP; and (e) neutral pH bu¡ers,
which impede barrier recovery after acute perturbations, presum-
ably by inactivating pH-dependent, ECP enzymes.
Still another category of biochemical enhancers utilizes ap-
proaches that alter either the formation of lamellar bilayers or
the supramolecular organization of preformed lamellar bilayers.
These include: (a) synthetic analogs of Chol, Cer, and FFA, such
as trans-vaccenic acid and epicholesterol, which induce abnormal-
ities in lamellar membrane organization; (b) complex precursors
of Chol, Cer, and FFA, such as sterol esters, which are not meta-
bolized e⁄ciently to their respective products in the SC; (c) su-
praphysiologic concentrations of physiologic lipids, such as Chol
SO4, which induce phase separation in preformed membrane bi-
layers; and (d) hydrolytic enzymes, such as acid ceramidase,
which degrade one or more of the three key SC species. Finally,
it should be noted that any single- or double-component mixture
of the three key lipids, or any mixture of all three species, which
includes a greater than 3-fold excess of one of the three key lipid
species, will delay barrier repair after acute perturbations. To-
gether, these strategies induce the formation of separate lamellar
and nonlamellar domains within the SC interstices. In most cases,
the basis for such domain separation relates to changes in the cri-
tical mole ratio, i.e., with deletion or excess of any one of the
three key lipids, a portion of the excess species no longer can re-
main in a well-organized lamellar phase. For example, a 50% re-
duction in Chol would result in an excess of both Cer and FFA,
with a portion of the excess forming a nonlamellar phase. The
result of phase separation is more permeable SC interstices, due
not only to deletion of a key hydrophobic lipid, but also to the
creation of additional penetration pathways, distinct from the pri-
mary, lamellar membrane route.
Based upon these studies in murine skin, then, strategies that
interfere with the synthesis, assembly, secretion, activation, pro-
cessing, or assembly/disassembly of the extracellular lamellar
membranes, could increase drug delivery by interfering with
permeability barrier homeostasis. These biochemical/metabolic
approaches can also be viewed vectorially, i.e., as operative within
di¡erent layers of the epidermis. For example, most lipid synth-
esis occurs within the basal layer, whereas LB formation, acidi¢-
cation, and secretion occur in suprabasal, nucleated cell layers.
Finally, ECP and membrane assembly occur even more distally,
i.e., within the SC interstices. Ultimately, strategies could be de-
ployed not only to target speci¢c biochemical mechanisms, but
also to take advantage of the localization and relative importance
of those steps that lead to the generation and maintenance of
functional SC extracellular lamellae.
EFFICACY, LIMITATIONS, AND POTENTIAL PITFALLS OF
BIOCHEMICAL APPROACH
To date the e¡ectiveness of these biochemical approaches for
transdermal drug delivery has been assessed primarily in adult
hairless mouse epidermis. In our initial studies, ca¡eine and lido-
caine were used as model permeants to assess whether their pene-
tration characteristics paralleled changes in TEWL produced by
metabolic inhibitors. The biochemical approaches here consisted
of the topical application of either drug plus either a Chol and/or
FA synthesis inhibitor in two di¡erent, conventional enhancer/
vehicle systems, dimethylsulfoxide or propylene glycol:ethanol
(7:3 vols), followed by assessment of bothTEWL and drug deliv-
ery. These studies showed that the biochemical enhancers acceler-
ated lidocaine and ca¡eine delivery several-fold across intact skin
above levels achieved with either of the chemical enhancer/vehi-
cle systems alone (Tsai et al, 1996). Moreover, the extent of
changes in TEWL correlated linearly with transdermal delivery
of both drugs. This study showed that biochemical enhancers
can increase transdermal drug delivery in a widely employed ani-
mal model. Additional work will be needed to explore whether
TEWL serves as a universal, accurate, and reproducible predictor
for transdermal delivery of drugs, with a broad range of physical-
chemical properties, and the ability of studies in animals to
predict increased drug delivery in humans. Nevertheless, these
preliminary studies suggest signi¢cant potential for the biochem-
ical/metabolic approach to increase transdermal drug delivery.
As noted above, many of the above approaches employ drugs
as the metabolic enhancer, which can impose substantial regula-
tory issues, unless (a) the enhancing drug is also a potential ther-
apeutic agent (e.g., statins to decrease lipid production in acne
vulgaris), or (b) the drug is already approved for systemic use
(e.g., the aSMase inhibitor, desipramine; statins, antimalarials,
calcium channel blockers). Furthermore, some metabolic enhan-
cers (e.g., monensin) though not approved for use in humans, are
already approved for veterinary use. In addition, the prior section
describes several approaches that do not use drugs (e.g., increased
Caþþ , neutral pH bu¡ers, complex lipids, lipid metabolites),
which should not impose regulatory hurdles.
For those approaches that do not produce a barrier defect in
intact skin, there is an implicit requirement for a ‘‘primary’’ en-
hancer to provide the initial barrier defect. Such an enhancing
system can be a combination of any of the standard physical or
chemical methods described above, coupled with one or more of
the biochemical/metabolic enhancers. The feasibility/e⁄ciency of
such a combined approach has been demonstrated for iontophor-
esis, coupled with the application of a single-component FFA
(oleic acid) and/or an unrelated chemical enhancer (propylene
glycol), as well as for chemical enhancers, coupled with lipid
synthesis inhibitors, as described above. Thus, it should be possi-
ble to devise, and even customize combinations of delivery meth-
ods, without the imposition of additional regulatory hurdles.
In summary, based upon extensive studies in mice, we have
proposed a number of biochemical/metabolic interventions that
could enhance transdermal drug delivery in humans. As these ap-
proaches become not only increasingly complex, but also more
e¡ective, they could impose not only signi¢cant regulatory hur-
dles, but also raise issues about increased xenobiote or microbial
Table III. Lipid synthetic and processing inhibitors that
modulate barrier homeostasis
Required
lipid Enzyme targets Examples
Cholesterol HMGCoA Reductase Lovastatin, £uvastatin
Free FattyAcids Acetyl CoA carboxylase TOFA
Secretory phospholipase A2 Bromphenacyl
bromide, MJ33
Ceramides Serine palmitoyl transferase b-chlorolanine
Glucosylceramide synthase Morpholino agents
(e.g., P4)
b-Glucocerebrosidase Conduritols
Acidic sphingomyelinase Desipramine
Abbreviations: TOFA: 5-(tetradecyloxy)-2-furancarboxylic acid; P4: d,1-threo-
1-phenyl-2-hexadecanoylamino-3-pyrrolidino-1-propanol; MJ33: 1-hexadecyl-3-
tri£uoroethylglycero-sn-2-phosphomethanol.
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access. Obviously, a more patent ‘‘window’’ across the SC raises
the theoretical risk of penetration not only of desirable entities,
but also of toxic substances or pathogenic microbes. One poten-
tial, salutory approach would be to utilize barrier repair technol-
ogy to ‘‘close the window’’after a ¢nite period of patency. Indeed,
as seen in Fig 2, this strategy can be used either (a) with coappli-
cations of physiologic lipids, to modify the extent of the original
window, or (b) to arbitrarily terminate the enhancing sequence,
by application of the physiologic lipids at a desirable point after
enhancer/drug applications.
Ms. LauraTeale capably prepared the manuscript.This work was supported by NIH
grants AR 19098 and AR39369, as well as the Medical Research Service, Depart-
ment ofVeterans A¡airs.
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